Literature DB >> 15652650

Antinociceptive action of hemopressin in experimental hyperalgesia.

Camila Squarzoni Dale1, Rosana de Lima Pagano, Vanessa Rioli, Stephen Hyslop, Renata Giorgi, Emer Suavinho Ferro.   

Abstract

Endogenous hemorphins, derived from degradation of the beta-chain of hemoglobin, lower arterial blood pressure and exert an antinociceptive action in experimental models of nociception. Hemopressin, derived from the alpha-chain of hemoglobin, also decreases blood pressure, but its effects on pain have not been studied. In this work, we examined the influence of hemopressin on inflammatory pain. Hemopressin reverted the hyperalgesia induced by either carrageenin or bradykinin when injected concomitantly or 2.5 h after the phlogistic agents. Hemopressin administered systemically also reverted the hyperalgesia induced by carrageenin. Naloxone did not prevent the antinociceptive action of this peptide. These data suggest that hemopressin inhibits peripheral hyperalgesic responses by mechanisms independent of opioid receptor activation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15652650     DOI: 10.1016/j.peptides.2004.10.026

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  16 in total

Review 1.  Hemoglobin-derived peptides as novel type of bioactive signaling molecules.

Authors:  Ivone Gomes; Camila S Dale; Kimbie Casten; Miriam A Geigner; Fabio C Gozzo; Emer S Ferro; Andrea S Heimann; Lakshmi A Devi
Journal:  AAPS J       Date:  2010-09-02       Impact factor: 4.009

Review 2.  Hemopressin and other bioactive peptides from cytosolic proteins: are these non-classical neuropeptides?

Authors:  Julia S Gelman; Lloyd D Fricker
Journal:  AAPS J       Date:  2010-04-10       Impact factor: 4.009

3.  The peptide hemopressin acts through CB1 cannabinoid receptors to reduce food intake in rats and mice.

Authors:  Garron T Dodd; Giacomo Mancini; Beat Lutz; Simon M Luckman
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

4.  Hemopressin is an inverse agonist of CB1 cannabinoid receptors.

Authors:  Andrea S Heimann; Ivone Gomes; Camila S Dale; Rosana L Pagano; Achla Gupta; Laura L de Souza; Augusto D Luchessi; Leandro M Castro; Renata Giorgi; Vanessa Rioli; Emer S Ferro; Lakshmi A Devi
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-12       Impact factor: 11.205

5.  Activation of spinal and supraspinal cannabinoid-1 receptors leads to antinociception in a rat model of neuropathic spinal cord injury pain.

Authors:  Aldric Hama; Jacqueline Sagen
Journal:  Brain Res       Date:  2011-07-26       Impact factor: 3.252

6.  Hemopressins and other hemoglobin-derived peptides in mouse brain: comparison between brain, blood, and heart peptidome and regulation in Cpefat/fat mice.

Authors:  Julia S Gelman; Juan Sironi; Leandro M Castro; Emer S Ferro; Lloyd D Fricker
Journal:  J Neurochem       Date:  2010-02-24       Impact factor: 5.372

7.  Interactions between cannabinoid and opioid receptors in a mouse model of diabetic neuropathy.

Authors:  Elaine F Toniolo; Achla Gupta; Adriano C Franciosi; Ivone Gomes; Lakshmi A Devi; Camila S Dale
Journal:  Pain       Date:  2021-10-27       Impact factor: 7.926

Review 8.  Modulation of the cannabinoid receptors by hemopressin peptides.

Authors:  Martha G Bomar; Amit K Galande
Journal:  Life Sci       Date:  2012-08-01       Impact factor: 5.037

9.  Hemopressin, an inverse agonist of cannabinoid receptors, inhibits neuropathic pain in rats.

Authors:  Elaine F Toniolo; Estêfani T Maique; Wilson A Ferreira; Andrea S Heimann; Emer S Ferro; Dinah L Ramos-Ortolaza; Lydia Miller; Lakshmi A Devi; Camila S Dale
Journal:  Peptides       Date:  2014-04-03       Impact factor: 3.750

10.  A novel peptide that improves metabolic parameters without adverse central nervous system effects.

Authors:  Patrícia Reckziegel; William T Festuccia; Luiz R G Britto; Karen L Lopes Jang; Carolina M Romão; Joel C Heimann; Manoela V Fogaça; Naielly S Rodrigues; Nicole R Silva; Francisco S Guimarães; Rosangela A S Eichler; Achla Gupta; Ivone Gomes; Lakshmi A Devi; Andrea S Heimann; Emer S Ferro
Journal:  Sci Rep       Date:  2017-11-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.